Abstract
Growth hormone insensitivity (GHI) is defined as the absence of an appropriate growth and metabolic response to endogenous GH or to GH administered at physiologic replacement dosage (1). Table 1 lists the known conditions associated with GH resistance and their clinical and biochemical features. Only GH receptor (GH-R) deficiency (GHRD) and GH-GHR signal transduction defects are appropriately described as primary GH resistance or insensitivity. Inability to generate insulin-like growth factor-I (IGF-I) resulting from mutation of the IGF-I gene (2) and resistance to IGF-I due to mutation of the IGF-I receptor (3) are properly considered primary IGF-I deficiency and IGF-I resistance.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Rosenbloom AL, Guevara-Aguirre J, Rosenfeld RG, Pollock BH. Growth in growth hormone insensitivity. Trends Endocrinol Metab 1994; 5: 296–303.
Woods KA, Camacho-Hübner C, Savage MO, Clark AJL. Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. N Engl J Med 1996; 335: 1363–1367.
Abizzajab MJ, Goddard A, Grigorescu F, Lautier C, Smith RJ, Chernausek SD. Human IGF-I receptor mutations associated with intrauterine and post-natal growth retardation. Proc Endocr Soc 82nd Ann. Mtg 2000 abstract #1947, p. 470.
Rivarola MA, Phillips JA III, Migeon CJ, Heinrich JJ, Hjelle BJ. Phenotypic heterogeneity in familial isolated growth hormone deficiency type I-A. J Clin Endocrinol Metab 1984; 59: 34–40.
Powell DR. Effects of renal failure on the growth hormone-insulin-like growth factor axis. J Pediatr 1997; 131: S13–516
De Groot LJ. Dangerous dogmas in medicine: the nonthyroid illness syndrome. J Clin Endocrinol Metab 1999; 84: 151–164.
Rosenfeld RG, Rosenbloom AL, Guevara-Aguirre J. Growth hormone (GH) insensitivity due to primary GH receptor deficiency. Endocr Rev 1994; 15: 369–390.
Postel-Vinay M-C, Kelly PA. Growth hormone receptor signalling. Bailliere’s Clin Endocrinol Metab 1996; 10: 323–326.
Leung DW, Spencer SA, Cachianes G. Growth hormone receptor and serum binding protein: purification, cloning and expression. Nature 1987; 330: 537–543.
Rosenbloom AL. Physiology and disorders of the growth hormone receptor (GHR) and GH-GHR signal transduction. Endocrine 2000; 12 (2): 107–119.
de Vos AM, Ultsch M, Kossiakoff AA. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 1992; 255: 306–312.
Rajaram S, Baylink DJ, Mohan S. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 1997; 18: 801–831.
Baxter RG, Binoux MA, Clemmons DR, et al. Recommendations for nomenclature of the insulin-like growth factor binding proteins superfamily. J Clin Endocrinol Metab 1998; 83: 3213.
Vaccarello MA, Diamond FB Jr, Guevara-Aguirre J, et al. Hormonal and metabolic effects and pharmacokinetics of recombinant human insulin-like growth factor-I in growth hormone receptor deficiency/Laron syndrome. J Clin Endocrinol Metab 1993; 77: 273–280.
Daughaday WH, Rotwein P. Insulin-like growth factors I and II: peptide, messenger ribonucleic acid and gene structures, serum and tissue concentrations. Endocr Rev 1989; 10: 68–91.
Laron Z, Pertzelan A, Mannheimer S. Genetic pituitary dwarfism with high serum concentration of growth hormone–a new inborn error of metabolism? Isr J Med Sci 1966; 2: 152–155.
Laron Z, Pertzelan A, Karp M. Pituitary dwarfism with high serum levels of growth hormone. Isr J Med Sci 1968; 4: 83–94.
Merimee TJ, Hall J, Rabinovitz D, McKusick VA, Rimoin DL. An unusual variety of endocrine dwarfism: Subresponsiveness to growth hormone in a sexually mature dwarf. Lancet 1998; 2: 191–193.
Daughaday WH, Laron Z, Pertzelan A, Heins JN. Defective sulfation factor generation: a possible etiological link in dwarfism. Trans Assoc Am Physicians 1969; 82: 129–138.
Bala RM, Beck JC. Fractionation studies on plasma of normals and patients with Laron dwarfism and hypopituitary gigantism. Can J Physiol Pharmacol 1973; 91: 845–852.
Eshet R, Laron Z, Brown M, Arnon R. Immunoreactive properties of the plasma hGH from patients with the syndrome of familial dwarfism and high plasma IR-hGH. J Clin Endocrinol Metab 1973; 37: 819–821.
Tsushima T, Shiu. RPC, Kelly PA, Friesen HG. Radioreceptor assay for human growth hormone and lactogens: structure-function studies and clinical applications. In: Raiti S (ed) Advances in Human Growth Hormone Research. USPHS, Bethesda, MD. USPHS-DHEW Publication 74–612, 1973, pp. 372–387.
Jacobs LS, Sneid DS, Garland JT, Laron Z, Daughaday WH. Receptor-active growth hormone in Laron dwarfism. J Clin Endocrinol Metab 1976; 42: 403–406.
Golde DW, Bersch N, Kaplan SA, Rimoin DL, Li CH. Peripheral unresponsiveness to human growth hormone in Laron dwarfism. N Engl J Med 1980; 303: 1156–1159.
Eshet R, Laron Z, Pertzelan A, Arnon R, Dintzman M. Defect of human growth hormone receptors in the liver of two patients with Laron-type dwarfism. Isr J Med Sci 1984; 20: 8–11.
Daughaday WH, Trivedi B. Absence of serum growth hormone binding protein in patients with growth hormone receptor deficiency (Laron dwarfism). Proc Natl Acad Sci USA 1987; 84: 4636–4640.
Baumann G, Shaw MA, Winter RJ. Absence of plasma growth hormone-binding protein in Larontype dwarfism. J Clin Endocrinol Metab 1987; 65: 814–816.
Godowski PJ, Leung DW, Meacham LR, et al. Characterization of the human growth hormone receptor gene and demonstration of a partial gene deletion in two patients with Laron-type dwarfism. Proc Natl Acad Sci USA 1989; 86: 8083–8087.
Pantel J, Machinis K, Sobrier ML, Duquesnoy P, Goossens M, Amselem S. Species-specific alternative splice mimicry at the growth hormone receptor locus revealed by the lineage of retroelements during primate evolution. A novel mechanism accounting for protein diversity between and within species. J Biol Chem 2000;275:18, 664–18, 669.
Rosenbloom AL, Guevara-Aguirre J. Lessons from the genetics of Laron syndrome. Trends Endocrinol Metab 1998; 9: 276–283.
Metherell LA, Munroe PB, Bjarnson R, et al. Proc Endocr Soc 82nd Ann Mtg 2000 absract # 1994, p. 482.
Attie KM, Carlsson LMS, Rundle AC, Sherman BM. Evidence for partial growth hormone insensitivity among patients with idiopathic short stature. J Pediatr 1995; 127: 244–250.
Sanchez JE, Perera E, Baumbach L, Cleveland WW. Growth hormone receptor mutations in children with idiopathic short stature. J Clin Endocrinol Metab 1998; 83: 4079–4083.
Kou K, Lajara R, Rotwein P. Amino acid substitutions in the intracellular part of the growth hormone receptor in a patient with the Laron syndrome. J Clin Endocrinol Metab 1993; 76: 54–59.
Goddard AD, Covello R, Luoh S-M, et al. Mutations of the growth hormone receptor in children with idiopathic short stature. N Eng J Med 1995; 333: 1093–1098.
Ayling RM, Ross R, Towner P, et al. A dominant-negative mutation of the growth hormone receptor causes familial short stature. Nature Genet 1997; 16: 13–14.
Iida K, Takahashi Y, Kaji H, et al. Growth hormone (GH) insensitivity syndrome with high serum GH binding protein levels caused by a heterozygous splice site mutation of the GH receptor gene producing a lack of intracellular domain. J Clin Endocrinol Metab 1998; 83: 531–537.
Iida K, Takahashi Y, Kaji H, et al. Functional characterization of truncated growth hormone (GH) receptor (1–277) causing partial GH insensitivity syndrome with high GH-binding protein. J Clin Endocrinol Metab 1999; 84: 1011–1016.
Dastot F, Sobrier ML, Duquesnoy P, Duriez B, Goosens M, Amselem S. Alternative spliced forms in the cytoplasmic domain of the human growth hormone (GH) receptor regulate its ability to generate a soluble GH binding protein. Proc Natl Acad Sci USA 1996;93:10, 723–10, 728.
Ross RJM, Esposito N, Shen XY, et al. A short isoform of the human growth hormone receptor functions as a dominant negative inhibitor of the full-length receptor and generates large amounts of binding protein. Mol Endocrinol 1997; 11: 265–273.
Amit T, Bergman T, Dastot F, Youdim MBH, Amselem S, Hochberg Z. A membrane-fixed, truncated isoform of the human growth hormone receptor. J Clin Endocrinol Metab 1997; 82: 3813–3817.
Iida K, Takahashi Y, Kaji H, et al. The C422F mutation of the growth hormone receptor gene is not responsible for short stature. J Clin Endocrinol Metab 1999; 84: 4214–4219.
Chujo S, Kaji H, Takahashi Y, Okimura Y, Abe H, Chihara K. No correlation of growth hormone receptor gene mutation P561T with body height. Eur J Endocrinol 1996; 134: 560–562.
Rosenbloom AL, Guevara-Aguirre J, Berg MA, Francke U. Stature in Ecuadorians heterozygous for the growth hormone receptor (GHR) gene E 180 splice mutation does not differ from that of homozygous normal relatives. J Clin Endocrinol Metab 1998; 83: 2373–2375.
Berg MA, Peoples R., Perez-Jurado L, et al. Receptor mutations and haplotypes in growth hormone receptor deficiency: a global survey and identification of the Ecuadorian E1 80 splice mutation in an oriental Jewish patient. Acta Paediatr 1994; 399 (Suppl): 112–114.
Laron Z, Klinger B, Eshet R, Kaneti H, Karasik A, Silbergeld A. Laron syndrome due to a post-receptor defect: response to IGF-I treatment. Isr J Med Sci 1993; 29: 757–763.
Freeth JS, Ayling RM, Whatmore AJ, et al. Human skin fibroblasts as a model of growth hormone (GH) action in GH receptor-positive Laron’s syndrome. Endocrinology 1997; 138: 55–61.
Freeth JS, Silva CM, Whatmore AJ, Clayton PE. Activation of the signal transducers and activators of transcription signaling pathway by growth hormone (GH) in skin fibroblasts from normal and GH binding protein-positive Laron syndrome children. Endocrinology 1998; 139: 20–28.
Rosenbloom AL, Francke U, Rosenfeld RG, Guevara-Aguirre J. Growth hormone receptor deficiency in Ecuador. J Clin Endocrinol Metab 1999; 84: 4436–4443.
Jorgensen JO, Müller J, Moller J, Wolthers T, Vahl N, Juul A, Skakkebaek NE, Christiansen JS. Adult growth hormone deficiency. Horm Res 1994; 42: 235–241.
Rosenbloom AL, Martinez V, Kranzler J, Bachrach LK, Rosenfeld RG, Guevara-Aguirre J. Natural history of growth hormone receptor deficiency. Acta Paediatr Suppl 1999; 428: 153–156.
Rudling M, Norstedt G, Olivecrona H, Reihnér E, Gustafsson J-A, Angelin B. Importance of growth hormone for the induction of hepatic low density lipoprotein receptors. Proc Natl Acad Sci 1992; 89: 6983–6987.
Laron Z, Lilos P, Klinger B. Growth curves for Laron syndrome. Arch Dis Child 1993; 68: 768–770.
Rose SR, Municchi G, Barnes KM, et al. Spontaneous growth hormone secretion increases during puberty in normal girls and boys. J Clin Endocrinol Metab 1991; 73: 428–435.
Crosnier H, Gourmelen M, Prëvot C, Rappaport R. Effects of nutrient intake on growth, insulin-like growth factors, and their binding proteins in a Laron-type dwarf. J Clin Endocrinol Metab 1993; 76: 248–250.
Schaefer GB, Rosenbloom AL, Guevara-Aguirre J, et al. Facial morphometry of Ecuadorian patients with growth hormone receptor deficiency/Laron syndrome. J Med Genet 1994; 31: 635–639.
Rosenbloom AL, Guevara-Aguirre J, Rosenfeld RG, Fielder PJ. The little women of Loja. Growth hormone receptor-deficiency in an inbred population of southern Ecuador. N Engl J Med 1990; 323: 1367–1374.
Rosenbloom AL, Selman-Almonte A, Brown MR, Fisher DA, Baumbach L, Parks JS. Clinical and biochemical phenotype of familial anterior hypopituitarism from mutation of PROP-1 gene. J Clin Endocrinol Metab 1999; 84: 50–57.
Rosenbloom AL, Guevara-Aguirre J, Fielder PJ, et al. Growth hormone receptor deficiency/Laron syndrome in Ecuador: Clinical and biochemical characteristics. Pediatr Adolesc Endocrinol 1993; 24: 34–52.
Bachrach LB, Marcus R, Ott SM, et al. Bone mineral, histomorphometry, and body composition in adults with growth hormone receptor deficiency. J Bone Mineral Res 1998; 3: 415–421.
Bandeira F, Camargo K, Caldas G, Rosenbloom AL, Stabler B, Underwood LE. Primary growth hormone insensitivity: case report. Arq Bras Endocrinol Metab 1997; 41: 198–200.
Frankel JJ, Laron Z. Psychological aspects of pituitary insufficiency in children and adolescents with special reference to growth hormone. Isr J Med Sci 1968; 4: 953–961.
Galatzer A, Aran O, Nagelberg N, Rubitzek J, Laron Z Cognitive and psychosocial functioning of young adults with Laron syndrome. Pediatr Adolesc Endocrinol 1993; 24: 53–60.
Maheshwari HG, Silverman BI, Dupuis J, Baumann G. phenotype and genetic analysis of a syndrome caused by an inactivating mutation in the growth hormone-releasing hormone receptor: dwarfism of Sindh. J Clin Endocrinol Metab 1998; 83: 4065–4074.
Woods KA, Dastot F, Preece MA, et al. Extensive personal experience. Phenotype: genotype relationships in growth hormone insensitivity syndrome. J Clin Endocrinol Metab 1997; 82, 3529–3535.
Guevara-Aguirre J, Rosenbloom AL. Psychosocial adaptation of Ecuadorian patients with growth hormone receptor deficiency/Laron syndrome. Pediatr Adolesc Endocrinol 1993; 24: 61–64.
Kranzler JH, Rosenbloom AL, Martinez V, Guevara-Aguirre J. Normal intelligence with severe IGF-I deficiency due to growth hormone receptor deficiency: a controlled study in genetically homogeneous population. J Clin Endocrinol Metab 1998; 83: 1953–1958.
Zhou Y, Xu BC, Maheshwari HG, et al. A mammalian model for the Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (the Laron mouse). Proc Natl Acad Sci USA 1997;94:13, 215–13, 220.
Beck KD, Powell-Braxton L, Widmer H-R, Valverde J, and Hofti, F. IGF-I gene disruption results in reduced brain size, CNS hypomyelination, and loss of hippocampal granule and striatal parvalbumin-containing neurons. Neuron 1995; 14: 717–730.
Gargosky SE, Wilson KF, Fielder PJ, et al. The composition and distribution of insulin-like growth factors (IGFs) and IGF-binding proteins (IGFBPs) in the serum of growth hormone receptor-deficient patients: effects of IGF-I therapy on IGFBP-3. J Clin Endocrinol Metab 1993; 77: 1683–1689.
Wilson KF, Fielder PJ, Guevara-Aguirre J, et al. Long-term effects of insulin-like growth factor (IGF)-I treatment on serum IGFs and IGF binding proteins in adolescent patients with growth hormone receptor deficiency. Clin Endocrinol 1995: 42, 399–407.
Guevara-Aguirre J, Vasconez O, et al. A randomized, double blind, placebo controlled trial on safety and efficacy of recombinant human insulin-like growth factor-I in children with growth hormone receptor deficiency. J Clin Endocrinol Metab 1995; 80: 1393–1398.
Guevara-Aguirre J, Rosenbloom AL, Vasconez O, Martinez V, Gargosky SE, Rosenfeld RG. Two year treatment of growth hormone receptor deficiency (GHRD) with recombinant insulin-like growth factor-I in 22 children: Comparison of two dosage levels and to GH treated GH deficiency. J Clin Endocrinol Metab 1997; 82: 629–633.
Ranke MB, Savage MO, Chatelain PG, et al. Insulin-like growth factor I improves height in growth hormone insensitivity: two years’ results. Horm Res 1995; 44: 253–264.
Rosenbloom AL, Guevara-Aguirre J, Fielder PJ, Gargosky S, Cohen P, Rosenfeld RG. Insulin-like growth factor binding proteins-2 and -3 in Ecuadorian patients with growth hormone receptor deficiency and their parents. Pediatr Adolesc Endocrinol 1993; 24: 185–191.
Woods KA, Savage MO. The Laron syndrome: typical and atypical forms. Bailliere’s Clin Endocrinol Metab 1996; 10: 371–387.
Rosenbloom AL. IGF-I treatment of growth hormone insensitivity. In: Rosenfeld RG, Roberts CT, eds. The IGF System: Molecular Biology, Physiology, and Clinical Applications. Totowa NJ; Humana Press, 1999, pp. 739–769.
Laron Z, Erster B, Klinger B, Anin S. Effect of acute administration of insulin-like growth factor I in patients with Laron-type dwarfism. Lancet 1988; 2: 1170–1172.
Laron Z, Klinger B, Silbergeld A, Lewin R, Erster B, Gil-Ad I. Intravenous administration of recombinant IGF-I lowers serum GHRH and TSH. Acta Endocrinologica 1990; 123: 378–382.
Klinger B, Garty M, Laron Z. Elimination characteristics of intravenously administered rIGF-I in Laron-type dwarfs. Dev Pharmacol Ther 1990; 15: 196–199.
Walker JL, Ginalska-Malinowska M, Romer TE, Pucilowska JB, Underwood LE. Effects of the infusion of insulin-like growth factor I in a child with growth hormone insensitivity syndrome (Laron syndrome). N Engl J Med 1991; 324: 1483–1488.
Laron Z, Klinger B, Jensen LT, Erster B. Biochemical and hormonal changes induced by one week of administration of rIGF-I to patients with Laron type dwarfism. Clin Endocrinol 1991; 35: 145–160.
Laron Z, Klinger B, Blum WF, Silbergeld A, Ranke MB. IGF binding protein 3 in patients with Laron type dwarfism: effect of exogenous rIGF-I. Clin Endocrinol 1992; 36: 301–304.
Lee PDK, Durham SK, Martinez V, Vasconez O, Powell DR, Guevara-Aguirre J. Kinetics of insulin-like growth factor (IGF) and IGF-binding protein responses to a single dose of growth hormone. J Clin Endocrinol Metab 1997; 82: 2266–2274.
Laron Z, Anin S, Klipper-Aurbach Y, Klinger B. Effects of insulin-like growth factor on linear growth, head circumference, and body fat in patients with Laron-type dwarfism. Lancet 1992; 339: 1258–1261.
Walker JL, Van Wyk JJ, Underwood LE. Stimulation of statural growth by recombinant insulin-like growth factor I in a child with growth hormone insensitivity syndrome (Laron type). J. Pediatr 1992; 121: 641–646.
Heinrichs C, Vis HL, Bergmann P, Wilton P, Bourguignon JP. Effects of 17 months treatment using recombinant insulin-like growth factor-I in two children with growth hormone insensitivity (Laron) syndrome. Clin Endocrinol 1993; 38: 647–651.
Ranke MB, Savage MO, Chatelain PG, P.eece MA, Rosenfeld RG, Wilton P. Long-term treatment of growth hormone insensitivity syndrome with IGF-I. Results of the European Multicentre Study. The Working Group on Growth Hormone Insensitivity Syndromes. Horm Res 1999; 51: 128–134.
Martinez V, Vasconez O, Martinez A, et al. Body changes in adolescent patients with growth hormone receptor deficiency receiving recombinant human insulin-like growth factor I and luteini zing hormone-releasing hormone analog: preliminary results. Acta Paediatr 1994; 399 (Suppl): 133–136.
Vasconez O, Martinez V, Martinez AL, et al. Heart rate increase in patients with growth hormone receptor deficiency treated with insulin-like growth factor I. Acta Paediatr 1994; 399 (Suppl): 137–139.
Klinger B, Laron Z. Three year IGF-I treatment of children with Laron syndrome. J Ped Endocrinol Metab 1995; 8: 149–158.
Klinger B, Anin S, Sibergeld A, Eshet R, Laron Z. Development of hyperandrogenism during treatment with insulin-like growth factor-I (IGF-I) in female patients with Laron syndrome. Clin. Endocrinol. 1998; 48: 81–87.
Backeljauw PF, Underwood LE, The GHIS Collaborative Group. Prolonged treatment with recombinant insulin-like growth factor-I in children with growth hormone insensitivity syndrome–a clinical research center study. J Clin Endocrinol Metab 1996; 81: 3312–3317.
Backeljauw PF, Kissoondial A, Underwood LE, Simmons KE. Effects of 4 years treatment with recombinant human insulin-like growth factor-I (rh IGF-I) on craniofacial growth in children with growth hormone insensitivity syndrome (GHIS). Horm Res 1997;48(Suppl 2):40(Abstract 243).
Backeljauw PF, Underwood LE. The GHIS collaborative group. Prolonged treatment with recombinant insulin-like growth factor-I (rh IGF-I) in children with growth hormone insensitivity syndrome (GHIS): 4 year update. Horm Res 1997;48(Suppl 2):15(Abstract 58).
Walker JL, Crock PA, Behncken SN, et al. A novel mutation affecting the interdomain link region of the growth hormone receptor in a Vietnamese girl, and response to long-term treatment with recombinant human insulin-like growth factor-I and luteinizing hormone-releasing hormone analog. J Clin Endocrinol Metab 1998; 83: 2554–2561.
Leonard J, Samuels M, Cotterill AM, Savage MO. Effects of recombinant insulin-like growth factor I on craniofacial morphology in growth hormone insensitivity. Acta Paediatr 1994; 399 (Suppl): 140–141.
Bjerknes R, Vesterhus P, Aarskog D. Increased neutrophil insulin-like growth factor-I (IGF-I) receptor expression and IGF-I-induced functional capacity in patients with untreated Laron syndrome. Eur J Endocrinol 1997; 136: 92–95.
Diamond F, Martinez V, Guevara-Aguirre J, et al. Immune function in patients with gorwth hormone receptor deficiency (GHRD). Proc Endocrinol Soc 78th Ann Mtg, 1996, vol 1, p. 276.
Le Roith D, Blakesley VA. The yin and the yang of the IGF system: immunological manifestations of GH resistance. Eur J Endocrinol 1997; 136: 33–34.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer Science+Business Media New York
About this chapter
Cite this chapter
Rosenbloom, A.L. (2003). Growth Hormone Insensitivity Syndrome. In: Radovick, S., MacGillivray, M.H. (eds) Pediatric Endocrinology. Contemporary Endocrinology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-336-1_2
Download citation
DOI: https://doi.org/10.1007/978-1-59259-336-1_2
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61737-268-1
Online ISBN: 978-1-59259-336-1
eBook Packages: Springer Book Archive